Open AccessUtility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
Author(s) -
Hamano Itsuto,
Hatakeyama Shingo,
Hamaya Tomoko,
Togashi Kyo,
Okamoto Teppei,
Yamamoto Hayato,
Yoneyama Tohru,
Yoneyama Takahiro,
Hashimoto Yasuhiro,
Ohyama Chikara
Publication year - 2020
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12172
Subject(s) - prostate cancer , medicine , enzalutamide , oncology , castration , biomarker , cell free fetal dna , cancer research , prostate , cancer , androgen receptor , biology , hormone , prenatal diagnosis , pregnancy , biochemistry , fetus , genetics
Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration‐resistant prostate cancer. Case presentation A 75‐year‐old man with newly diagnosed prostate cancer (serum prostate‐specific antigen 4891 ng/mL, Gleason score 4 + 5 = 9, cT3bN1M1) was referred to our department. He first received sequential hormonal therapies and was consequently diagnosed metastatic castration‐resistant prostate cancer 64 months after initial treatment. He underwent serial examinations of plasma cell‐free DNA, including concentration, androgen receptor amplification, TP53 point mutation, and PTEN loss. Only the cell‐free DNA concentration increased along with disease progression and declined after the administration of abiraterone and enzalutamide. Conclusion This case presented that cell‐free DNA concentration was possibly correlated with response to castration‐resistant prostate cancer treatment and disease progression. Cell‐free DNA concentration was proposed as a potential prognostic biomarker of metastatic castration‐resistant prostate cancer.